Skip to content

Christopher Paul Cannon

Brigham and Women's Hospital

4 papers in the Anchorcite directory, published between 2004 and 2019, cited 23,161 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2009 · 7,173 citations

    BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose,…

  2. Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations

    BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…

  3. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine · 2004 · 4,966 citations

    BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10…

  4. Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine · 2015 · 4,600 citations

    BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.…

Metadata from OpenAlex (CC0).